Citation-example-systematic-meta-review

Generated Narrative

url: http://hl7.org/fhir/Citation/citation-example-systematic-meta-review

identifier: FEvIR Object Identifier: 27121

title: SMR Sterne JAC JAMA 32876694

status: active

description: A systematic review included in the Steroids SMR Project

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper:

Summaries

Classifications

statusDate

activity: ROB assessment ()

actual: true

period: ?? --> 2021-06-07

statusDate

activity: Author contact ()

actual: true

period: 2021-06-07 --> (ongoing)

citedArtifact

identifier: id: 32876694, pii: 2770279, id: 10.1001/jama.2020.17023, id: PMC7489434

relatedIdentifier: id: CRD42020197242

dateAccessed: 2021-02-15

Titles

-	Type	Language	Text
*	primary-human-use ()	English (Tags for the Identification of Languages#en)	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.

Abstracts

-	Type	Text
*	Primary human use (CitedArtifactAbstractType#primary-human-use)	<AbstractText Label="Importance">Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support.</AbstractText><AbstractText Label="Objective">To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.</AbstractText><AbstractText Label="Design, Setting, and Participants">Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance-weighted fixed-effect meta-analysis of overall mortality, with the association between the intervention and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp adjustment) and an inverse variance-weighted fixed-effect analysis using risk ratios.</AbstractText><AbstractText Label="Exposures">Patients had been randomized to receive systemic dexamethasone, hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo (1025 patients).</AbstractText><AbstractText Label="Main Outcomes and Measures">The primary outcome measure was all-cause mortality at 28 days after randomization. A secondary outcome was investigator-defined serious adverse events.</AbstractText><AbstractText Label="Results">A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years]; 488 [29%] women) were included in the analysis. Risk of bias was assessed as "low" for 6 of the 7 mortality results and as "some concerns" in 1 trial because of the randomization method. Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were 222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the 1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82]; P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the trial results (I2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI, 0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths). Among the 6 trials that reported serious adverse events, 64 events occurred among 354 patients randomized to corticosteroids and 80 events occurred among 342 patients randomized to usual care or placebo.</AbstractText><AbstractText Label="Conclusions and Relevance">In this prospective meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.</AbstractText>

publicationForm

PublishedIns

-	Type	Identifier	Title	PublisherLocation
*	Periodical (PublishedInType#D020492)	ISSN Type: 1538-3598, ISOAbbreviation: JAMA, ISSN Linking: 0098-7484, Medline Title Abbreviation: JAMA, NLM Unique ID: 7501160	JAMA	United States

periodicRelease

citedMedium: Internet (journal-issue-medium#Internet)

volume: 324

issue: 13

DateOfPublications

-	Date	Year	Month	Day
*	2020-10-06	2020	10	06

language: English (Tags for the Identification of Languages#en)

pageString: 1330-1341

webLocation

classifier: DOI Based (ArtifactUrlClassifier#doi-based)

url: http://doi.org/10.1001/jama.2020.17023

webLocation

classifier: on PubMed (ArtifactUrlClassifier[5.0.0-snapshot1]#abstract "Abstract")

url: https://pubmed.ncbi.nlm.nih.gov/32876694/

webLocation

classifier: on JAMA (ArtifactUrlClassifier[5.0.0-snapshot1]#full-text "Full-Text")

url: https://jamanetwork.com/journals/jama/fullarticle/2770279

classification

type: Steroids SMR project use ()

classifier: primary article (), Unclear risk of bias ()

WhoClassifieds

-	Person	FreeToShare
*	: Brian S. Alper	false

classification

type: UC Description ()

classifier: To assess systemic corticosteroids on 28-day mortality in critically ill patients with COVID-19 ()

WhoClassifieds

-	Person	Organization	FreeToShare
*	: Dr. Ethan Molitch	: University of Chicago	true

classification

type: Knowledge Artifact Type (CitedArtifactClassificationType#knowledge-artifact-type)

classifier: Journal Article (CitationArtifactClassifier#D016428)

WhoClassifieds

-	Publisher	ClassifierCopyright	FreeToShare
*	: Computable Publishing LLC	https://creativecommons.org/licenses/by-nc-sa/4.0	true

classification

type: Publishing Model (CitedArtifactClassificationType#publishing-model)

classifier: Print (CitationArtifactClassifier#Print)

classification

type: Chemical (CitedArtifactClassificationType#chemical)

classifier: Adrenal Cortex Hormones (chemical-substances#0; #D000305), Glucocorticoids (chemical-substances#0; #D005938), Dexamethasone (chemical-substances#7S5I7G3JQL; #D003907), Hydrocortisone (chemical-substances#WI4X0X7BPJ; #D006854), Methylprednisolone (chemical-substances#X4W7ZR7023; #D008775)

classification

type: MeSH heading (CitedArtifactClassificationType#mesh-heading)

classifier: Adrenal Cortex Hormones (#D000305; #Q000627 "therapeutic use"; [not stated]#Y), Betacoronavirus (#D000073640), COVID-19 (#D000086382), Cause of Death (#D002423), Coronavirus Infections (#D018352; #Q000188 "drug therapy"; [not stated]#Y; #Q000401 "mortality"; [not stated]#N), Critical Illness (#D016638), Dexamethasone (#D003907; #Q000627 "therapeutic use"; [not stated]#N), Glucocorticoids (#D005938; #Q000627 "therapeutic use"; [not stated]#Y), Humans (#D006801), Hydrocortisone (#D006854; #Q000627 "therapeutic use"; [not stated]#N), Methylprednisolone (#D008775; #Q000627 "therapeutic use"; [not stated]#N), Pandemics (#D058873), Pneumonia, Viral (#D011024; #Q000188 "drug therapy"; [not stated]#Y; #Q000401 "mortality"; [not stated]#N), Randomized Controlled Trials as Topic (#D016032), SARS-CoV-2 (#D000086402)

classification

type: Publication type (CitedArtifactClassificationType#publication-type)

classifier: Journal Article (#D016428), Meta-Analysis (#D017418), Research Support, Non-U.S. Gov't (#D013485)

classification

type: Supplemental MeSH for Protocol (CitedArtifactClassificationType#supplemental-mesh-protocol)

classifier: COVID-19 drug treatment (#C000705127)

classification

type: Citation subset (CitedArtifactClassificationType#citation-subset)

classifier: AIM (elements_descriptions.html#citationsubset#AIM), IM (elements_descriptions.html#citationsubset#IM)

classification

type: Funding ()

classifier: The World Health Organization (Conflict of interest statements included notes on several fundings for co-investigators as well, albeit not directly funding this meta-analysis) ()

WhoClassifieds

-	Person	Organization	FreeToShare
*	: Erfan Shamsoddin	: COVID-19 Knowledge Accelerator	true

contributorship

complete: true

entry

collectiveName: WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

entry

name: Jonathan A C Sterne

initials: JAC

affiliationInfo

affiliation: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.

affiliationInfo

affiliation: NIHR Bristol Biomedical Research Centre, Bristol, England.

telecom: jonathan.sterne@bristol.ac.uk

correspondingContact: true

entry

name: Srinivas Murthy

initials: S

AffiliationInfos

-	Affiliation
*	Department of Pediatrics, University of British Columbia, Vancouver, Canada.

entry

name: Janet V Diaz

initials: JV

AffiliationInfos

-	Affiliation
*	Clinical Unit, Health Emergencies Programme, World Health Organization, Geneva, Switzerland.

entry

name: Arthur S Slutsky

initials: AS

AffiliationInfos

-	Affiliation
*	Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

entry

name: Jesús Villar

initials: J

affiliationInfo

affiliation: Research Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain.

affiliationInfo

affiliation: CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.

entry

name: Derek C Angus

initials: DC

AffiliationInfos

-	Affiliation
*	Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

entry

name: Djillali Annane

initials: D

AffiliationInfos

-	Affiliation
*	Department of Intensive Care, Raymond Poincaré Hospital (APHP), School of Medicine Simone Veil, University Paris Saclay-UVSQ, Paris, France.

entry

name: Luciano Cesar Pontes Azevedo

initials: LCP

affiliationInfo

affiliation: Hospital Sírio-Libanês, São Paulo, Brazil.

affiliationInfo

affiliation: Emergency Medicine Department, University of São Paulo School of Medicine, São Paulo, Brazil.

entry

name: Otavio Berwanger

initials: O

AffiliationInfos

-	Affiliation
*	Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil.

entry

name: Alexandre B Cavalcanti

initials: AB

AffiliationInfos

-	Affiliation
*	HCor Research Insitute, São Paulo, Brazil.

entry

name: Pierre-Francois Dequin

initials: PF

affiliationInfo

affiliation: Médecine Intensive-Réanimation, INSERM CIC1415, CHRU de Tours, Tours, France.

affiliationInfo

affiliation: CRICS-TriGGERSep Network, Centre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France.

entry

name: Bin Du

initials: B

AffiliationInfos

-	Affiliation
*	Peking Union Medical College Hospital, Beijing, China.

entry

name: Jonathan Emberson

initials: J

affiliationInfo

affiliation: Nuffield Department of Population Health, University of Oxford, Oxford, England.

affiliationInfo

affiliation: MRC Population Health Research Unit, University of Oxford, Oxford, England.

entry

name: David Fisher

initials: D

AffiliationInfos

-	Affiliation
*	MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, Faculty of Population Health Sciences, University College London, London, England.

entry

name: Bruno Giraudeau

initials: B

AffiliationInfos

-	Affiliation
*	CIC INSERM 1415-CHRU de Tours, Tours, France.

entry

name: Anthony C Gordon

initials: AC

AffiliationInfos

-	Affiliation
*	Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, England.

entry

name: Anders Granholm

initials: A

AffiliationInfos

-	Affiliation
*	Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

entry

name: Cameron Green

initials: C

AffiliationInfos

-	Affiliation
*	Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

entry

name: Richard Haynes

initials: R

affiliationInfo

affiliation: Nuffield Department of Population Health, University of Oxford, Oxford, England.

affiliationInfo

affiliation: MRC Population Health Research Unit, University of Oxford, Oxford, England.

entry

name: Nicholas Heming

initials: N

AffiliationInfos

-	Affiliation
*	Department of Intensive Care, Raymond Poincaré Hospital (APHP), School of Medicine Simone Veil, University Paris Saclay-UVSQ, Paris, France.

entry

name: Julian P T Higgins

initials: JPT

affiliationInfo

affiliation: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.

affiliationInfo

affiliation: NIHR Bristol Biomedical Research Centre, Bristol, England.

affiliationInfo

affiliation: NIHR Applied Research Collaboration West, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England.

entry

name: Peter Horby

initials: P

AffiliationInfos

-	Affiliation
*	Nuffield Department of Medicine, University of Oxford, Oxford, England.

entry

name: Peter Jüni

initials: P

AffiliationInfos

-	Affiliation
*	Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

entry

name: Martin J Landray

initials: MJ

affiliationInfo

affiliation: Nuffield Department of Population Health, University of Oxford, Oxford, England.

affiliationInfo

affiliation: MRC Population Health Research Unit, University of Oxford, Oxford, England.

affiliationInfo

affiliation: NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, England.

entry

name: Amelie Le Gouge

initials: A

AffiliationInfos

-	Affiliation
*	CIC INSERM 1415-CHRU de Tours, Tours, France.

entry

name: Marie Leclerc

initials: M

AffiliationInfos

-	Affiliation
*	CIC INSERM 1415-CHRU de Tours, Tours, France.

entry

name: Wei Shen Lim

initials: WS

AffiliationInfos

-	Affiliation
*	Respiratory Medicine Department, Nottingham University Hospitals NHS Trust, Nottingham, England.

entry

name: Flávia R Machado

initials: FR

AffiliationInfos

-	Affiliation
*	Anesthesiology, Pain, and Intensive Care Department, Federal University of São Paulo, São Paulo, Brazil.

entry

name: Colin McArthur

initials: C

affiliationInfo

affiliation: Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

affiliationInfo

affiliation: Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.

entry

name: Ferhat Meziani

initials: F

affiliationInfo

affiliation: Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France.

affiliationInfo

affiliation: INSERM UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France.

entry

name: Morten Hylander Møller

initials: MH

AffiliationInfos

-	Affiliation
*	Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

entry

name: Anders Perner

initials: A

AffiliationInfos

-	Affiliation
*	Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

entry

name: Marie Warrer Petersen

initials: MW

AffiliationInfos

-	Affiliation
*	Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

entry

name: Jelena Savovic

initials: J

affiliationInfo

affiliation: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.

affiliationInfo

affiliation: NIHR Applied Research Collaboration West, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England.

entry

name: Bruno Tomazini

initials: B

affiliationInfo

affiliation: Hospital Sírio-Libanês, São Paulo, Brazil.

affiliationInfo

affiliation: Department of Surgery, School of Medicine, University of São Paulo, São Paulo, Brazil.

entry

name: Viviane C Veiga

initials: VC

AffiliationInfos

-	Affiliation
*	BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.

entry

name: Steve Webb

initials: S

affiliationInfo

affiliation: Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

affiliationInfo

affiliation: St John of God Healthcare, Subiaco, Australia.

entry

name: John C Marshall

initials: JC

AffiliationInfos

-	Affiliation
*	Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Summaries

-	Type	Source	Value
*	Author string (ContributorSummaryType[5.0.0-snapshot1]#author-string)	articleCopy ()	The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Authors and Members of the Writing Committee: Jonathan A. C. Sterne, MA, MSc, PhD; Srinivas Murthy, MD, MSc; Janet V. Diaz, MD; Arthur S. Slutsky, CM, MD; Jesús Villar, MD, PhD; Derek C. Angus, MD, MPH; Djillali Annane, MD, PhD; Luciano Cesar Pontes Azevedo, MD, PhD; Otavio Berwanger, MD, PhD; Alexandre B. Cavalcanti, MD, PhD; Pierre-Francois Dequin, MD, PhD; Bin Du, MD; Jonathan Emberson, PhD; David Fisher, MSc; Bruno Giraudeau, PhD; Anthony C. Gordon, MBBS, MD; Anders Granholm, MD; Cameron Green, MSc; Richard Haynes, DM; Nicholas Heming, MD, PhD; Julian P. T. Higgins, BA, PhD; Peter Horby, PhD; Peter Jüni, MD; Martin J. Landray, PhD; Amelie Le Gouge, MSc; Marie Leclerc, MSc; Wei Shen Lim, BMedSci, BMBS, DM; Flávia R. Machado, MD, PhD; Colin McArthur, MBChB; Ferhat Meziani, MD, PhD; Morten Hylander Møller, MD, PhD; Anders Perner, MD, PhD; Marie Warrer Petersen, MD; Jelena Savović, BPharm, MSc, PhD; Bruno Tomazini, MD; Viviane C. Veiga, MD, PhD; Steve Webb, MBBS, MPH, PhD; John C. Marshall, MD.